DiaCarta's Novel XNA Technology Rapidly Detects Raging New SARS-CoV-2 Variants
Share this article Share this article RICHMOND, Calif., April 22, 2021 /PRNewswire/ -- DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced the publication of a study entitled "A Rapid SARS-CoV-2 Variant Detection by Molecular-Clamping Based RT-qPCR" in MedRxiV (https://doi.org/10.1101/2021.04.01.21254484) that demonstrates the enhanced sensitivity and specificity using its proprietary XNA based Molecular Clamping Technology that uses innovative synthetic Xenonucleic acid molecular oligomers (XNA) that hyb...